title: Safety of topical methimazole for the treatment of melasma. Transdermal absorption, the effect on thyroid function and cutaneous adverse effects.
abstract: Methimazole is an oral antithyroid compound that exhibits a skin-depigmenting effect when used topically. However, the effect of topical methimazole on thyroid function has not been reported. This study was aimed at assessing the safety of topical methimazole used to treat pigmented lesions, without affecting thyroid hormones due to systemic delivery. The pharmacokinetics of methimazole, either applied in the form of a 5% topical formulation to facial skin or taken orally in the form of a 5-mg tablet by 6 volunteers, were determined. In addition, the effect of long-term topical applications of 5% methimazole on the function of the thyroid gland in 20 patients with epidermal melasma was determined following 6 weeks of once-daily application. Cutaneous adverse effects of topical methimazole were determined. From 15 min up to 24 h after application, methimazole was undetectable in the serum of the individuals receiving single topical methimazole dosing. Methimazole, however, was detected in serum after 15 min of oral administration and remained detectable in serum up to 24 h after administration. Long-term topical methimazole applications in melasma patients did not induce any significant changes in serum TSH, free thyroxine and free triiodothyronine levels. Topical methimazole was well tolerated by the patients and did not induce any significant cutaneous side effects. Present data together with the previously shown non-cytotoxic and non-mutagenic characteristics of methimazole indicate that this agent could be considered as a safe skin-depigmenting compound for topical treatment of skin hyperpigmentary disorders in humans.
authors.affiliation: Department of Dermatology, Geneva University Hospital, Geneva, Switzerland.
authors.forename: B
authors.initials: B
authors.lastname: Kasraee
authors.forename: G H
authors.initials: GH
authors.lastname: Safaee Ardekani
authors.forename: A
authors.initials: A
authors.lastname: Parhizgar
authors.forename: F
authors.initials: F
authors.lastname: Handjani
authors.forename: G R
authors.initials: GR
authors.lastname: Omrani
authors.forename: M
authors.initials: M
authors.lastname: Samani
authors.forename: M
authors.initials: M
authors.lastname: Nikbakhsh
authors.forename: N
authors.initials: N
authors.lastname: Tanideh
authors.forename: A
authors.initials: A
authors.lastname: Eshraghian
authors.forename: O
authors.initials: O
authors.lastname: Sorg
authors.forename: J H
authors.initials: JH
authors.lastname: Saurat
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D013956:Antithyroid Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008548:Melanosis / Q000188:drug therapy*; D008713:Methimazole / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D008875:Middle Aged; D012869:Skin Absorption; D013960:Thyroid Function Tests; D013972:Thyrotropin / Q000097:blood / Q000187:drug effects; D013974:Thyroxine / Q000097:blood / Q000187:drug effects; D013997:Time Factors; D014284:Triiodothyronine / Q000097:blood / Q000187:drug effects; D055815:Young Adult
chemical_list: D013956:Antithyroid Agents; D014284:Triiodothyronine; D008713:Methimazole; D013972:Thyrotropin; D013974:Thyroxine